178 related articles for article (PubMed ID: 32518946)
21. Somatic mutations in
Gao LM; Zhao S; Zhang WY; Wang M; Li HF; Lizaso A; Liu WP
Cancer Biol Ther; 2019; 20(10):1319-1327. PubMed ID: 31311407
[TBL] [Abstract][Full Text] [Related]
22. Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27.
Salzer E; Daschkey S; Choo S; Gombert M; Santos-Valente E; Ginzel S; Schwendinger M; Haas OA; Fritsch G; Pickl WF; Förster-Waldl E; Borkhardt A; Boztug K; Bienemann K; Seidel MG
Haematologica; 2013 Mar; 98(3):473-8. PubMed ID: 22801960
[TBL] [Abstract][Full Text] [Related]
23. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice.
Muto H; Sakata-Yanagimoto M; Nagae G; Shiozawa Y; Miyake Y; Yoshida K; Enami T; Kamada Y; Kato T; Uchida K; Nanmoku T; Obara N; Suzukawa K; Sanada M; Nakamura N; Aburatani H; Ogawa S; Chiba S
Blood Cancer J; 2014 Dec; 4(12):e264. PubMed ID: 25501021
[TBL] [Abstract][Full Text] [Related]
24. Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
Pastoret C; Desmots F; Drillet G; Le Gallou S; Boulland ML; Thannberger A; Doncker AV; Salaun V; Damaj GL; Veyrat-Masson R; Tournilhac O; Moignet A; Pangault C; Roussel M; Fest T; Lamy T
Blood; 2021 Jun; 137(23):3237-3250. PubMed ID: 33512451
[TBL] [Abstract][Full Text] [Related]
25. B-cell tumor development in
Mouly E; Ghamlouch H; Della-Valle V; Scourzic L; Quivoron C; Roos-Weil D; Pawlikowska P; Saada V; Diop MK; Lopez CK; Fontenay M; Dessen P; Touw IP; Mercher T; Aoufouchi S; Bernard OA
Blood Adv; 2018 Mar; 2(6):703-714. PubMed ID: 29581109
[TBL] [Abstract][Full Text] [Related]
26. Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.
Pan F; Wingo TS; Zhao Z; Gao R; Makishima H; Qu G; Lin L; Yu M; Ortega JR; Wang J; Nazha A; Chen L; Yao B; Liu C; Chen S; Weeks O; Ni H; Phillips BL; Huang S; Wang J; He C; Li GM; Radivoyevitch T; Aifantis I; Maciejewski JP; Yang FC; Jin P; Xu M
Nat Commun; 2017 Apr; 8():15102. PubMed ID: 28440315
[TBL] [Abstract][Full Text] [Related]
27. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.
Lemonnier F; Couronné L; Parrens M; Jaïs JP; Travert M; Lamant L; Tournillac O; Rousset T; Fabiani B; Cairns RA; Mak T; Bastard C; Bernard OA; de Leval L; Gaulard P
Blood; 2012 Aug; 120(7):1466-9. PubMed ID: 22760778
[TBL] [Abstract][Full Text] [Related]
28. T-cell lymphoma with a granulomatous lesion of the lungs after autologous hematopoietic stem cell transplantation for Epstein-Barr virus-positive diffuse large B-cell lymphoma: a unique rare case of metachronous B-cell and T-cell lymphoma.
Kajimoto Y; Terasaki Y; Terasaki M; Kunugi S; Okabe Y; Wakita S; Inokuchi K; Shimizu A
Diagn Pathol; 2020 Oct; 15(1):125. PubMed ID: 33036636
[TBL] [Abstract][Full Text] [Related]
29. TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma.
Schwartz FH; Cai Q; Fellmann E; Hartmann S; Mäyränpää MI; Karjalainen-Lindsberg ML; Sundström C; Scholtysik R; Hansmann ML; Küppers R
J Pathol; 2017 Jun; 242(2):129-133. PubMed ID: 28337768
[TBL] [Abstract][Full Text] [Related]
30. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
[TBL] [Abstract][Full Text] [Related]
31. Multistep tumorigenesis in peripheral T cell lymphoma.
Sakata-Yanagimoto M
Int J Hematol; 2015 Nov; 102(5):523-7. PubMed ID: 25628103
[TBL] [Abstract][Full Text] [Related]
32. Dysregulation of TET2 in hematologic malignancies.
Chiba S
Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
[TBL] [Abstract][Full Text] [Related]
33. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract][Full Text] [Related]
34. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host.
Meisel M; Hinterleitner R; Pacis A; Chen L; Earley ZM; Mayassi T; Pierre JF; Ernest JD; Galipeau HJ; Thuille N; Bouziat R; Buscarlet M; Ringus DL; Wang Y; Li Y; Dinh V; Kim SM; McDonald BD; Zurenski MA; Musch MW; Furtado GC; Lira SA; Baier G; Chang EB; Eren AM; Weber CR; Busque L; Godley LA; Verdú EF; Barreiro LB; Jabri B
Nature; 2018 May; 557(7706):580-584. PubMed ID: 29769727
[TBL] [Abstract][Full Text] [Related]
35. Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome.
Sano S; Oshima K; Wang Y; MacLauchlan S; Katanasaka Y; Sano M; Zuriaga MA; Yoshiyama M; Goukassian D; Cooper MA; Fuster JJ; Walsh K
J Am Coll Cardiol; 2018 Feb; 71(8):875-886. PubMed ID: 29471939
[TBL] [Abstract][Full Text] [Related]
36. DNA methylcytosine dioxygenase ten-eleven translocation 2 enhances lipopolysaccharide-induced cytokine expression in human dental pulp cells by regulating MyD88 hydroxymethylation.
Wang X; Feng Z; Li Q; Yi B; Xu Q
Cell Tissue Res; 2018 Aug; 373(2):477-485. PubMed ID: 29654353
[TBL] [Abstract][Full Text] [Related]
37. [Primary immunodeficiencies. Clinical features and variant forms].
Fontán Casariego G
Allergol Immunopathol (Madr); 2001; 29(3):101-7. PubMed ID: 11434882
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis Susceptibility Prolongs the Lack of Memory B Cells in Acute Leukemic Patients After Allogeneic Hematopoietic Stem Cell Transplantation.
Mensen A; Oh Y; Becker SC; Hemmati PG; Jehn C; Westermann J; Szyska M; Göldner H; Dörken B; Scheibenbogen C; Arnold R; Na IK
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1895-906. PubMed ID: 26271190
[TBL] [Abstract][Full Text] [Related]
39. MYC deregulates TET1 and TET2 expression to control global DNA (hydroxy)methylation and gene expression to maintain a neoplastic phenotype in T-ALL.
Poole CJ; Lodh A; Choi JH; van Riggelen J
Epigenetics Chromatin; 2019 Jul; 12(1):41. PubMed ID: 31266538
[TBL] [Abstract][Full Text] [Related]
40. Fatal Lymphoproliferative Disease in Two Siblings Lacking Functional FAAP24.
Daschkey S; Bienemann K; Schuster V; Kreth HW; Linka RM; Hönscheid A; Fritz G; Johannes C; Fleckenstein B; Kempkes B; Gombert M; Ginzel S; Borkhardt A
J Clin Immunol; 2016 Oct; 36(7):684-92. PubMed ID: 27473539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
